Short‐Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis

To determine the prognostic value of pulmonary function test (PFT) trends at 1 and 2 years in interstitial lung disease (ILD) associated with systemic sclerosis (SSc).

[1]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[2]  G. Raghu,et al.  Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[3]  N. Goh,et al.  Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. , 2013, Rheumatology.

[4]  M. Baron,et al.  Validation of potential classification criteria for systemic sclerosis , 2012, Arthritis care & research.

[5]  A. Nicholson,et al.  Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[6]  H. Collard,et al.  Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan , 2013, Annals of Internal Medicine.

[7]  Artemis-Ipf Investigators.  Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial , 2013 .

[8]  G. Koch,et al.  A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials , 2015, European Respiratory Journal.

[9]  G. Raghu,et al.  Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. , 2005, Chest.

[10]  A. Wells.  Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear , 2012, Thorax.

[11]  A. Nicholson,et al.  Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. , 2002, American journal of respiratory and critical care medicine.

[12]  F. Martinez,et al.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[13]  D. Hansell,et al.  Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. , 2007, Arthritis and rheumatism.

[14]  A. Nicholson,et al.  Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia , 2012, Respirology.

[15]  D. Hansell,et al.  Interstitial lung disease in systemic sclerosis: a simple staging system. , 2008, American journal of respiratory and critical care medicine.

[16]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.

[17]  D. Hansell,et al.  Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. , 1997, American journal of respiratory and critical care medicine.

[18]  A. Nicholson,et al.  CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. , 2004, Radiology.

[19]  T. Medsger,et al.  Isolated diffusing capacity reduction in systemic sclerosis. , 1992, Arthritis and rheumatism.

[20]  Joyce S Lee,et al.  Predicting survival across chronic interstitial lung disease: the ILD-GAP model. , 2014, Chest.

[21]  Athol U. Wells,et al.  Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group , 2015, The Journal of Rheumatology.

[22]  N. Goh,et al.  Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. , 2015, Clinical and experimental rheumatology.

[23]  N. Peek,et al.  Fibrotic idiopathic interstitial pneumonias: Mortality is linked to a decline in gas transfer , 2010, Respirology.

[24]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[25]  A. Nicholson,et al.  Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. , 2003, American journal of respiratory and critical care medicine.

[26]  H. Collard,et al.  Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. , 2015, The Lancet. Respiratory medicine.

[27]  H. Collard,et al.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[28]  H. Heinzl,et al.  Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study , 2013, Annals of the rheumatic diseases.

[29]  W. Travis,et al.  Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. , 2005, American journal of respiratory and critical care medicine.

[30]  H. Moutsopoulos,et al.  Determinants of pulmonary arterial hypertension in scleroderma. , 2007, Seminars in arthritis and rheumatism.

[31]  D. Hansell,et al.  Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. , 1994, American journal of respiratory and critical care medicine.

[32]  F. Martinez,et al.  Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema , 2010, European Respiratory Journal.

[33]  Joyce S Lee,et al.  Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis , 2012, Thorax.